Lataa...
KRAS-mutant colon cancer cells respond to combined treatment of ABT263 and axitinib
Significant challenges to develop selective and effective pharmacological inhibitors for important oncoproteins like RAS continue impeding the success to treat cancers driven by such mutations. In the present study, the ABT263 and axitinib combination imposed synergistic effects on RAS-mutant colon...
Tallennettuna:
| Julkaisussa: | Biosci Rep |
|---|---|
| Päätekijät: | , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Portland Press Ltd.
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6400663/ https://ncbi.nlm.nih.gov/pubmed/30674639 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1042/BSR20181786 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|